NASDAQ:URGN UroGen Pharma - URGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $10.35 -0.04 (-0.38%) (As of 02/1/2023 10:43 AM ET) Add Compare Share Share Today's Range$10.09▼$10.5750-Day Range$7.55▼$10.3952-Week Range$4.85▼$12.63Volume41,689 shsAverage Volume118,119 shsMarket Capitalization$235.36 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability UroGen Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside73.2% Upside$18.00 Price TargetShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.50) to ($3.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector157th out of 1,053 stocksPharmaceutical Preparations Industry67th out of 519 stocks 3.3 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, UroGen Pharma has a forecasted upside of 73.2% from its current price of $10.39.Amount of Analyst CoverageUroGen Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.93% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in UroGen Pharma has recently decreased by 15.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 3.6 News and Social Media Coverage News SentimentUroGen Pharma has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for UroGen Pharma this week, compared to 1 article on an average week.Search Interest1 people have searched for URGN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders14.00% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.90% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($4.50) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About UroGen Pharma (NASDAQ:URGN) StockUroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.Read More Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock News HeadlinesJanuary 11, 2023 | markets.businessinsider.comUroGen Reports Results Of First Post-Commercial Utilization Review Of JELMYTOJanuary 11, 2023 | finance.yahoo.comResults of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial CancerFebruary 1, 2023 | Investing Trends (Ad)Move Over Lithium – 220 Pounds of Graphite In Every EV BatteryInvestors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.January 9, 2023 | finance.yahoo.comThe past five years for UroGen Pharma (NASDAQ:URGN) investors has not been profitableDecember 22, 2022 | seekingalpha.comURGN UroGen Pharma Ltd.December 19, 2022 | finance.yahoo.comUroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)December 13, 2022 | finance.yahoo.comWith 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big gunsDecember 2, 2022 | finance.yahoo.comUroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder CancerFebruary 1, 2023 | PressReach (Ad)Top AI Tech Stock To WatchToday's stock market news features a Robotics stock with blue sky potential.December 2, 2022 | markets.businessinsider.comUroGen : Phase 3 Data Show JELMYTO Provides Effective & Durable Kidney-sparing Treatment OptionDecember 1, 2022 | finance.yahoo.comUroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial CancerNovember 21, 2022 | finance.yahoo.comUroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx ConferenceNovember 21, 2022 | seekingalpha.comUroGen Pharma: Jelmyto Sales Growing Steadily, Concerns RemainNovember 16, 2022 | finance.yahoo.comSome Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) EstimatesNovember 14, 2022 | finance.yahoo.comUroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial CarcinomaNovember 12, 2022 | finance.yahoo.comUroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | seekingalpha.comUroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comUroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 10, 2022 | finance.yahoo.comUrogen Pharma (URGN) Reports Q3 Loss, Lags Revenue EstimatesNovember 9, 2022 | finance.yahoo.comUroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of DirectorsNovember 3, 2022 | finance.yahoo.comUroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022October 11, 2022 | finance.yahoo.com10 Best Immunotherapy Stocks To Buy NowOctober 11, 2022 | finance.yahoo.comUroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder CancersOctober 1, 2022 | finance.yahoo.comUroGen Pharma Ltd. (URGN)September 28, 2022 | markets.businessinsider.comUroGen Pharma Announces Label Change For JELMYTO - Quick FactsSeptember 28, 2022 | finance.yahoo.comFDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following ReconstitutionSeptember 12, 2022 | finance.yahoo.comUroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of DirectorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Company Calendar Last Earnings11/10/2022Today2/01/2023Next Earnings (Estimated)3/20/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees195Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$23.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+73.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,820,000.00 Net Margins-175.16% Pretax Margin-171.63% Return on EquityN/A Return on Assets-78.11% Debt Debt-to-Equity RatioN/A Current Ratio6.40 Quick Ratio6.14 Sales & Book Value Annual Sales$48.04 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares22,740,000Free Float19,557,000Market Cap$235.36 million OptionableOptionable Beta0.78 Key ExecutivesElizabeth BarrettPresident, Chief Executive Officer & DirectorDong KimChief Financial & Accounting OfficerMarina KonortyEVP-Research & Development & Technical OperationsMark P. SchoenbergChief Medical OfficerMoran MieronDirector-Research & Pre-Clinical AffairsKey CompetitorsCitius PharmaceuticalsNASDAQ:CTXRImmutepNASDAQ:IMMPNature's Sunshine ProductsNASDAQ:NATRKemPharmNASDAQ:KMPHCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 1,500 shares on 1/27/2023Ownership: 0.321%ARK Investment Management LLCSold 84,763 shares on 1/24/2023Ownership: 0.866%Balyasny Asset Management LLCBought 11,868 shares on 11/16/2022Ownership: 0.052%BlackRock Inc.Bought 4,366 shares on 11/15/2022Ownership: 1.516%State Street CorpSold 33,039 shares on 11/15/2022Ownership: 0.451%View All Insider TransactionsView All Institutional Transactions URGN Stock - Frequently Asked Questions Should I buy or sell UroGen Pharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" URGN shares. View URGN analyst ratings or view top-rated stocks. What is UroGen Pharma's stock price forecast for 2023? 3 Wall Street research analysts have issued twelve-month target prices for UroGen Pharma's stock. Their URGN share price forecasts range from $11.00 to $23.00. On average, they expect the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 73.9% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts. How have URGN shares performed in 2023? UroGen Pharma's stock was trading at $8.87 at the start of the year. Since then, URGN stock has increased by 16.7% and is now trading at $10.35. View the best growth stocks for 2023 here. Are investors shorting UroGen Pharma? UroGen Pharma saw a decrease in short interest in January. As of January 15th, there was short interest totaling 569,600 shares, a decrease of 15.2% from the December 31st total of 671,700 shares. Based on an average daily volume of 73,500 shares, the days-to-cover ratio is currently 7.7 days. Currently, 2.9% of the shares of the company are sold short. View UroGen Pharma's Short Interest. When is UroGen Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023. View our URGN earnings forecast. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.22) by $0.09. The business had revenue of $16.10 million for the quarter, compared to analysts' expectations of $20.30 million. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU). When did UroGen Pharma IPO? (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. What is UroGen Pharma's stock symbol? UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN." Who are UroGen Pharma's major shareholders? UroGen Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.87%), Rice Hall James & Associates LLC (0.32%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is UroGen Pharma's stock price today? One share of URGN stock can currently be purchased for approximately $10.35. How much money does UroGen Pharma make? UroGen Pharma (NASDAQ:URGN) has a market capitalization of $235.36 million and generates $48.04 million in revenue each year. The company earns $-110,820,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis. How many employees does UroGen Pharma have? The company employs 195 workers across the globe. How can I contact UroGen Pharma? UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com. This page (NASDAQ:URGN) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.